SANOFI SA INHABER EO 2/ FR0000120578 /
| 2024-04-19 8:14:54 AM | Chg. -0.12 | Volume | Bid9:59:59 PM | Ask9:59:59 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 85.30EUR | -0.14% | 0 Turnover: 0.00 |
-Bid Size: - | -Ask Size: - | 108.93 bill.EUR | 4.33% | 20.16 |
GlobeNewswire
04-17
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...
GlobeNewswire
04-10
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
04-09
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...
GlobeNewswire
03-14
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Busi...
GlobeNewswire
03-14
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
GlobeNewswire
03-11
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance ...
GlobeNewswire
03-05
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (F...
GlobeNewswire
02-28
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized ...
GlobeNewswire
02-27
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...
GlobeNewswire
02-24
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significa...
GlobeNewswire
02-23
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” co...
GlobeNewswire
02-23
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...
GlobeNewswire
02-23
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inf...
GlobeNewswire
02-22
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoi...
GlobeNewswire
02-22
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Bus...
GlobeNewswire
02-16
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
GlobeNewswire
02-16
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
GlobeNewswire
02-15
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corp...
GlobeNewswire
02-15
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy ...
